Single-chain chimeric polypeptides and uses thereof
Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.
1. A single-chain chimeric polypeptide comprising:
(i) a first target-binding domain;
(ii) a soluble tissue factor domain that does not have coagulation activity; and
(iii) a second target-binding domain,
wherein the single-chain chimeric polypeptide does not stimulate blood coagulation in a mammal.
2. The single-chain chimeric polypeptide of claim 1 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other.
3. The single-chain chimeric polypeptide of claim 1 , wherein the single-chain chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain.
4. The single-chain chimeric polypeptide of claim 1 , wherein the soluble tissue factor domain and the second target-binding domain directly abut each other.
5. The single-chain chimeric polypeptide of claim 1 , wherein the single-chain chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the second target-binding domain.
6. The single-chain chimeric polypeptide of claim 1 , wherein the first target-binding domain and the second target-binding domain bind specifically to the same antigen.
7. The single-chain chimeric polypeptide of claim 1 , wherein the first target-binding domain and the second target-binding domain bind specifically to different antigens.
8. The single-chain chimeric polypeptide of claim 1 , wherein one or both of the first target-binding domain and the second target-binding domain is an antigen-binding domain.
9. The single-chain chimeric polypeptide of claim 1 , wherein one or both of the first target-binding domain and the second target-binding domain bind to a target selected from the group consisting of: CD16a, CD28, CD3, CD33, CD20, CD19, CD22, CD123, IL-1R, IL-1, VEGF, IL-6R, IL-4, IL-10, PDL-1, TIGIT, PD-1, TIM3, CTLA4, MICA, MICB, IL-6, IL-8, TNFα, CD26α, CD36, ULBP2, CD30, CD200, IGF-1R, MUC4AC, MUC5AC, Trop-2, CMET, EGFR, HER1, HER2, HER3, PSMA, CEA, B7H3, EPCAM, BCMA, P-cadherin, CEACAM5, a UL16-binding protein, HLA-DR, DLL4, TYRO3, AXL, MER, CD122, CD155, PDGFDD, a ligand of TGF-β receptor II (TGF-βRII), a ligand of TGF-βRIII, a ligand of DNAM1, a ligand of NKp46, a ligand of NKp44, a ligand of NKG2D, a ligand of NKp30, a ligand for a scMHCI, a ligand for a scMHCII, a ligand for a scTCR, a receptor for IL-1, a receptor for IL-2, a receptor for IL-3, a receptor for IL-7, a receptor for IL-8, a receptor for IL-10, a receptor for IL-12, a receptor for IL-15, a receptor for IL-17, a receptor for IL-18, a receptor for IL-21, a receptor for PDGF-DD, a receptor for stem cell factor (SCF), a receptor for stem cell-like tyrosine kinase 3 ligand (FLT3L), a receptor for MICA, a receptor for MICB, a receptor for a ULP16-binding protein, a receptor for CD155, a receptor for CD122, and a receptor for CD28.
10. The single-chain chimeric polypeptide of claim 1 , wherein one or both of the first target-binding domain and the second target-binding domain is a soluble interleukin, a soluble cytokine protein, or a soluble cell surface protein.
11. The single-chain chimeric polypeptide of claim 10 , wherein the soluble interleukin, soluble cytokine protein, or soluble cell surface protein is selected from the group consisting of: IL-1, IL-2, IL-3, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, IL-21, PDGF-D, SCF, FLT3L, MICA, MICB, and a ULP16-binding protein.
12. The single-chain chimeric polypeptide of claim 1 , wherein one or both of the first target-binding domain and the second target-binding domain is a soluble interleukin receptor, a soluble cytokine receptor, or a soluble cell surface receptor.
13. The single-chain chimeric polypeptide of claim 12 , wherein the soluble interleukin receptor, the soluble cytokine receptor, or the soluble cell surface receptor is a soluble TGF-β receptor II (TGF-βRII), a soluble TGF-βRIII, a soluble NKG2D, a soluble NKp30, a soluble NKp44, a soluble NKp46, a soluble DNAM-1, a scMHCI, a scMHCII, a scTCR, a soluble CD155, or a soluble CD28.
14. The single-chain chimeric polypeptide of claim 1 , wherein the soluble tissue factor domain is a soluble human tissue factor domain that does not have coagulation activity.
15. A composition comprising the single-chain chimeric polypeptide of claim 1 .
16. A kit comprising at least one dose of the composition of claim 15 .
17. The single-chain chimeric polypeptide of claim 1 , wherein the soluble tissue factor domain comprises or consists of a sequence from a wildtype soluble human tissue factor.
18. The single-chain chimeric polypeptide of claim 1 , wherein the first target-binding domain and the second target-binding domain are human IL-2.
19. The single-chain chimeric polypeptide of claim 18 , wherein the human IL-2 comprises SEQ ID NO: 28.
20. The single-chain chimeric polypeptide of claim 19 , wherein the soluble tissue factor domain comprises SEQ ID NO: 9.
21. A single-chain chimeric polypeptide comprising a sequence of SEQ ID NO: 108.
22. A composition comprising the single-chain chimeric polypeptide of claim 21 .
23. A kit comprising at least one dose of the composition of claim 22 .
24. A single-chain chimeric polypeptide comprising a sequence of SEQ ID NO: 110.
25. A composition comprising the single-chain chimeric polypeptide of claim 24 .
26. A kit comprising at least one dose of the composition of claim 25 .